Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives – San Diego Biotechnology Network
Alterome Therapeutics Raises $132 Million in Series B Financing Led by Goldman Sachs Alternatives – San Diego Biotechnology Network Alterome Therapeutics, a biopharmaceutical company pioneering the development of small molecule targeted therapies for cancer, has closed a $132 million Series B financing led by Goldman Sachs Alternatives. Proceeds will be used to support the advancement of multiple wholly-owned pipeline programs into the clinic, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor. The financing was led by Goldm.
Pubblicato : 2 mesi fa di in Business Finance
SAN DIEGO–(BUSINESS WIRE)–Alterome Therapeutics, Inc., a biopharmaceutical company pioneering the development of next generation, small molecule targeted therapies for the treatment of cancer, today announced the closing of a $132 million Series B financing. Proceeds from the fundraise will be used to support the advancement of multiple wholly-owned pipeline programs into the clinic, including a highly specific AKT1 E17K inhibitor and a KRAS selective inhibitor. The financing was led by Goldm
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
Temi: Venture Capital, Markets, Startups, Series B